Placebo | Page 42 of 57 | SpiritIndia.com

Cervical Cancer :: Merck’s cervical cancer vaccine Gardasil in CDC’s Vaccines for Children

Merck & Co., Inc. announced that the U.S. Centers for Disease Control and Prevention (CDC) has added Merck’s cervical cancer vaccine, GARDASIL? [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] to the CDC’s Vaccines for Children (VFC) contract for girls and women aged 9 to 18. GARDASIL was approved on June 8 by the Food and Drug Administration (FDA) for use in girls and women ages 9 to 26 years. GARDASIL is the world’s first and only vaccine available for the prevention of HPV types 16- and 18-related cervical cancer, cervical pre-cancers (CIN 2/3 and AIS), vulvar pre-cancers (VIN 2/3) and vaginal pre-cancers (VaIN 2/3) and for the prevention of genital warts and low-grade cervical lesions (CIN 1) caused by HPV types 6, 11, 16 and 18.

Incontinence :: Magnetic stimulation of the pelvic floor not effective in the control of urinary incontinence

Magnetic stimulation of the pelvic floor found not effective in the control of urinary incontinence. A study was conducted to determine the safety and effectiveness of non-invasive static magnetic stimulation (SMS) of the pelvic floor compared to placebo in the treatment of women aged 60 years and over with urinary incontinence in Australia.

Restless Legs Syndrome :: Boehringer Ingelheim’s pramipexole effective in RLS patients

New data presented today show patients taking pramipexole (Mirapexin?/ Sifrol?) can experience significant improvements in a broad range of symptoms associated with Restless Legs Syndrome (RLS).1 In an additional study presented today, pramipexole was also shown to be well tolerated in RLS patients affected by concomitant diseases, which are commonly experienced in this patient group.2 The results of the studies were presented at the 10th International Congress of Parkinson?s Disease and Movement Disorders (MDS) in Kyoto, Japan.

Parkinson’s Disease :: Boehringer Ingelheim’s pramipexole, mirapexin/sifrol to improve depressive and motivational symptoms

New data presented today from a meta-analysis* of nearly 1,300 Parkinson?s disease (PD) patients, indicate that pramipexole (Mirapexin?/Sifrol?) has a beneficial effect on depressive and motivational symptoms in PD.1 This confirms findings from previously published clinical trials,2,3,4 and is in addition to its established efficacy in controlling motor symptoms. These findings are of particular interest as mood symptoms in PD can affect up to 50 percent of the patient population.1,5 The data were presented at the 10th International Congress of Parkinson?s Disease and Movement Disorders (MDS) in Kyoto, Japan.

Lymphoma :: Berlex Oncology Evaluating Combination Therapy for Non-Hodgkin’s Lymphoma

Berlex Oncology, a business unit of Berlex Laboratories, a U.S. affiliate of Schering AG, Germany (FSE: SCH; NYSE: SHR), today announced that a national clinical study is underway investigating a new approach to treating follicular B-cell lymphoma, a sub-type of non-Hodgkin?s lymphoma (NHL). NHL is the fifth most common form of cancer in the United States, with more than 56,000 new cases diagnosed each year. Follicular B-cell lymphoma is an indolent, or slow-growing, type of NHL that comprises approximately 30% of all diagnosed cases.

Hepatitis :: Glaxo eltrombopag improved platelet count in hepatitis C patients with thrombocytopenia

GlaxoSmithKline plc [NYSE:GSK, LSE:GSK] announced results from a global Phase II study of eltrombopag, an investigational non-peptide oral platelet growth factor. In this study of 74 hepatitis C patients with thrombocytopenia, (a condition where the blood has low platelet levels) more than 95% (p< 0.001) of patients treated with the highest dose of eltrombopag (75mg) had increased platelet counts. In addition, 71% - 91% of patients in all treatment groups were able to initiate antiviral therapy with pegylated interferon-α (IFN) and ribavirin, and 65% were able to be maintained on therapy.1 Full results from this Phase II study are being presented today at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, Massachusetts.

Weight Loss :: Supplements help avoid ‘Weight Creep’ from Turkey and Sugar Plums – Tonalin CLA Study

CLA may serve critical role in preventing weight and fat gain during year-end holidays and with normal aging. Avoiding ‘weight creep’ from turkey and sugar plums is the theme of a consumer PR campaign Cognis Nutrition & Health is rolling out in time for the holiday season based on a Tonalin? CLA study recently published online in the prestigious International Journal of Obesity. The research suggests that Tonalin? CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process.

Diabetes :: Herbal medicine Milk Thistle, Silybum marianum, silymarin helps sugar-control in type II diabetes

Diabetes is a growing health problem. Giving antioxidants is recognised as one way of helping people with diabetes to control their blood sugar levels. The herbal medicine extracted from seeds of the Milk Thistle, Silybum marianum (silymarin) is known to have antioxidant properties and research published this week in Phytotherapy Research shows that this extract can help people significantly lower the amount of sugar bound to haemoglobin in blood, as well as reducing fasting blood sugar levels.

Hypertension :: Results of TROPHY study on hypertension are misleading

There may be as many as 70 million Americans with prehypertension. If these people can be treated pharmacologically to avoid or delay progression to clinical hypertension, there would be significant benefits to them and the overall health of the population. The recent TROPHY study seems to lead to that conclusion. However, two editorials published in the November issue of the American Journal of Hypertension emphatically argue that the study is flawed and the conclusions reached are misleading.

ADHD :: Daytrana, methylphenidate transdermal system provides individualized ADHD symptom management

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that its Attention Deficit Hyperactivity Disorder (ADHD) patch, DAYTRANA tm (methylphenidate transdermal system), has significant efficacy in reducing the symptoms of ADHD in children aged 6 to 12 years, even when the ADHD patch is taken off earlier than the recommended nine hours. The ability to remove the patch earlier than the recommended nine-hour wear time allows physicians the opportunity to manage the potential for late-day side effects, such as lack of appetite or difficulty sleeping. These phase IIIb clinical trial results were reported today at a major scientific and educational meeting of child and adolescent psychiatrists in San Diego, Calif.